Infliximab biosimilar - Merck & Co/Samsung Bioepis

Drug Profile

Infliximab biosimilar - Merck & Co/Samsung Bioepis

Alternative Names: Flixabi; Infliximab - Samsung Bioepis; RENFLEXIS; SB 2

Latest Information Update: 26 Jul 2017

Price : $50

At a glance

  • Originator Samsung Bioepis
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 24 Jul 2017 Launched for Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis, Ulcerative colitis, Crohn's disease and Rheumatoid arthritis in USA (IV)
  • 14 Jun 2017 Efficacy data from a phase III trial in Rheumatoid arthritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 24 Apr 2017 Registered for Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis, Ulcerative colitis, Crohn's disease and Rheumatoid arthritis in Australia (IV) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top